The worst-case scenario: treatment of periprosthetic femoral fracture with coexistent periprosthetic infection-a prospective and consecutive clinical study.


Journal

Archives of orthopaedic and trauma surgery
ISSN: 1434-3916
Titre abrégé: Arch Orthop Trauma Surg
Pays: Germany
ID NLM: 9011043

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 26 02 2019
pubmed: 23 8 2019
medline: 3 1 2020
entrez: 22 8 2019
Statut: ppublish

Résumé

The simultaneous occurrence of periprosthetic fracture (PPF) and periprosthetic joint infection (PJI) is among the most devastating complications in arthroplasty and carries the risk of limb loss. For the first time, this study will describe the characteristics, treatment concepts, and outcomes of this complication. Patients were consecutively included who were treated at our specialized interdisciplinary department between 2015 and 2016 with a PJI and an additional PPF of the hip. The treatment algorithm followed a three-step procedure: the complete removal of any foreign material (step 1), fracture stabilization by plate, intramedullary rod osteosynthesis or cerclages using an additional spacer (step 2), and reimplantation of a new prosthesis (step 3). Overall, eight cases [four male, four female, mean age 77 years (55-91)] were included. The mean follow-up was 34 ± 8 months. The fractures included one PPF Vancouver B1, three B2/3, and four type C. Most frequent microbes were CNS (Coagulase-negative staphylococci) (n = 4), Cutibacterium (n = 2) and Staphylococcus aureus (n = 2). Mixed infections (≥ 2 microorganisms) occurred in five cases. The time between explanation and reimplantation was 42 ± 34 (range 7-123) days. A re-infection took place in one, a re-revision in four cases, and in five cases fracture healing was noticed. In all eight cases, freedom from the infection and limb preservation could be achieved. PPF in the case of a PJI is a devastating situation and a huge challenge. Extremity preservation should be the primary goal. The described procedure offers a possible solution.

Sections du résumé

BACKGROUND BACKGROUND
The simultaneous occurrence of periprosthetic fracture (PPF) and periprosthetic joint infection (PJI) is among the most devastating complications in arthroplasty and carries the risk of limb loss. For the first time, this study will describe the characteristics, treatment concepts, and outcomes of this complication.
METHODS METHODS
Patients were consecutively included who were treated at our specialized interdisciplinary department between 2015 and 2016 with a PJI and an additional PPF of the hip. The treatment algorithm followed a three-step procedure: the complete removal of any foreign material (step 1), fracture stabilization by plate, intramedullary rod osteosynthesis or cerclages using an additional spacer (step 2), and reimplantation of a new prosthesis (step 3).
RESULTS RESULTS
Overall, eight cases [four male, four female, mean age 77 years (55-91)] were included. The mean follow-up was 34 ± 8 months. The fractures included one PPF Vancouver B1, three B2/3, and four type C. Most frequent microbes were CNS (Coagulase-negative staphylococci) (n = 4), Cutibacterium (n = 2) and Staphylococcus aureus (n = 2). Mixed infections (≥ 2 microorganisms) occurred in five cases. The time between explanation and reimplantation was 42 ± 34 (range 7-123) days. A re-infection took place in one, a re-revision in four cases, and in five cases fracture healing was noticed. In all eight cases, freedom from the infection and limb preservation could be achieved.
CONCLUSION CONCLUSIONS
PPF in the case of a PJI is a devastating situation and a huge challenge. Extremity preservation should be the primary goal. The described procedure offers a possible solution.

Identifiants

pubmed: 31432205
doi: 10.1007/s00402-019-03263-y
pii: 10.1007/s00402-019-03263-y
doi:

Types de publication

Clinical Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1461-1470

Auteurs

Michael Müller (M)

Department of Orthopaedics, Center for Musculoskeletal Surgery, Charité-University Medicine, Charitéplatz 1, 10117, Berlin, Germany.

Tobias Winkler (T)

Department of Orthopaedics, Center for Musculoskeletal Surgery, Charité-University Medicine, Charitéplatz 1, 10117, Berlin, Germany.
Julius Wolff Institute and Berlin Brandenburg Center for Regenerative Therapies, Charité-University Medicine, Augustenburger Platz 1, 13353, Berlin, Germany.

Sven Märdian (S)

Department of Orthopaedics, Center for Musculoskeletal Surgery, Charité-University Medicine, Charitéplatz 1, 10117, Berlin, Germany.

Andrej Trampuz (A)

Department of Orthopaedics, Center for Musculoskeletal Surgery, Charité-University Medicine, Charitéplatz 1, 10117, Berlin, Germany.

Nora Renz (N)

Department of Orthopaedics, Center for Musculoskeletal Surgery, Charité-University Medicine, Charitéplatz 1, 10117, Berlin, Germany.

Carsten Perka (C)

Department of Orthopaedics, Center for Musculoskeletal Surgery, Charité-University Medicine, Charitéplatz 1, 10117, Berlin, Germany.

Daniel Karczewski (D)

Department of Orthopaedics, Center for Musculoskeletal Surgery, Charité-University Medicine, Charitéplatz 1, 10117, Berlin, Germany. daniel.karczewski@charite.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH